Mar 25, 2026 | Press Releases
Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding PartnershipsConference Call to be Held Today at 1:30 PM PT / 4:30 PM ET SAN ANTONIO, TX / ACCESS Newswire / March 25, 2026 / Tivic...
Mar 24, 2026 | Press Releases
SAN ANTONIO, TX / ACCESS Newswire / March 24, 2026 / Tivic Health Systems (Nasdaq:TIVC)Dear Valued Shareholders,As I assume the role of Chief Executive Officer at Tivic, my immediate priority is to establish a transparent dialogue with you regarding our current...
Mar 20, 2026 | Press Releases
SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it will report its year-end financial results for 2025 via pre-recorded conference call and webcast on...
Mar 4, 2026 | Press Releases
SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) (“Tivic” or the “Company”), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as...
Feb 18, 2026 | Press Releases
Initial presentation on January 26, 2026 showcased Entolimod’s potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), a...